Pilot trial of N-acetylcysteine and tigecycline as a catheter-lock solution for treatment of hemodialysis catheter-associated bacteremia.
Author(s): Aslam S, Trautner BW, Ramanathan V, Darouiche RO
Affiliation(s): Sections of Infectious Disease, Department of Medicine, Baylor College of Medicine, the Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas 77030, USA. saslam@bcm.tmc.edu
Publication date & source: 2008-09, Infect Control Hosp Epidemiol., 29(9):894-7.
Publication type: Clinical Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
We evaluated a catheter-lock solution consisting of N-acetylcysteine, tigecycline, and heparin for catheter salvage in patients with hemodialysis catheter-associated bacteremia. Eighteen case patients received the catheter-lock solution for 14 days plus systemic antibiotic therapy. Treatment was successful for 15 (83%) of the 18 case patients within 90 days of follow-up, with a median catheter retention interval of 64.5 days.
|